Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant effects on reward-related fMRI in alcoholism risk
NCT03341715Phase 1Completed
- Sponsor
- Yale University
- Start
- Jun 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in alcohol use disorder (AUD) comparing Mavoglurant with Placebo (2 arms). Primary endpoint: MRI Monetary Incentive Delay (MID) task activation. Started Jun 2018; status: completed.
02
Drugs
mavoglurant
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT03341715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03341715.